# Amplyx Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amplyx-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.amplyx.com
- Total disclosed funding: $135M
- Latest round: Series C (May 19, 2020)
- Investors on record: 13

## About

Founded in 2006 and based in California, US, Amplyx Pharmaceuticals, Inc. operates as a developer of small molecule drugs for the treatment of oncology and infectious diseases. The company was founded by Andre Marquis, Gerald Crabtree and Mitchell Mutz. In May 2020, Amplyx Pharmaceuticals, Inc. raised USD 53 million in series C funding led by returning investor Sofinnova Ventures and in April 2021, Amplyx Pharmaceuticals, Inc. was acquired by Pfizer Inc.

Amplyx Pharmaceuticals develops small molecule drugs with enhanced efficacy and lower toxicity by adding a second small molecule to an existing drug. Amplyx drug development pipeline has three product candidates under clinical development called fosmanogepix, APX2039 and MAU868.

Fosmanogepix is a novel broad-spectrum antifungal agent being evaluated in Phase 2 clinical trials in patients with life-threatening fungal infections caused by aspergillosis and candidemia. MAU868 is a monoclonal antibody used for the treatment of clinically significant BK virus infection in people who have received either a kidney or hematopoietic cell transplant.

The company’s future strategy includes advancing the clinical development of its product candidates.

## Funding rounds

- Series C, May 19, 2020, $53M — New Enterprise Associates, Sofinnova Investments, Pappas Capital, RiverVest Ventures Partners, Adage Capital Management, Pfizer Inc., Lundbeckfond Ventures, 503 Partners, BioMed Ventures, Arix Bioscience
- Series C, Jul 31, 2017, $40M — New Enterprise Associates, Sofinnova Investments, Pappas Capital, RiverVest Ventures Partners, Lundbeckfond Ventures, 503 Partners, BioMed Ventures, Arix Bioscience
- Series B, Nov 11, 2015, $41M — New Enterprise Associates, RiverVest Ventures Partners, BioMed Ventures
- Series A, Apr 8, 2010, $1.5M — Tech Coast Angels, Golden Seeds, Life Science Angels, Inc.

## Investors

- Tech Coast Angels — Series A
- Golden Seeds (https://capitalatlas.ai/funds/golden-seeds) — Series A
- Life Science Angels, Inc. — Series A
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B, Series C
- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Series B, Series C
- BioMed Ventures — Series B, Series C
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series C
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series C
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series C
- 503 Partners (https://capitalatlas.ai/funds/503-partners) — Series C
- Arix Bioscience (https://capitalatlas.ai/funds/arix-bioscience) — Series C
- Adage Capital Management — Series C
- Pfizer Inc. — Series C